The Zhitong Finance App learned that BridgeBio Pharma (BBIO.US) announced on Wednesday that its heart disease treatment acoramidis (US brand name: Attruby) performed better than Pfe.US (PFE.US) competitor drug tafamidis (US brand name Vyndamax) in a real-world study.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.